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surgical resection with adjuvant radiation therapy, but recur-
rence is inevitable as with other malignant gliomas5,7,26).
AO/AOA is expected to show a high response rate to chemo-
therapy among malignant gliomas, especially in subgroup with 
1p-19q co-deletion. Reported results of PCV chemotherapy for 
newly diagnosed AO/AOA are fairly high, up to 75% although 
with significant occurrence of hematologic toxicity5,6,19). Thus, 
availability of salvage chemotherapy for recurrent AO/AOA has 
been limited by clinical parameters such as chemo-experience 
and old age, and reports of response rates are rare and vary by 
regimen in a range of 23-77%1,3,4,9-11,28,32). 
Among those experiences, temozolomide (TMZ) is high-
INTRODUCTION
Anaplastic oligodendroglioma (AO) is a relatively rare tumor 
comprising 5-25% of malignant gliomas and having a variable 
clinical course22,23). Appearance of a mixed astrocytic compo-
nent on pathological examination confers a histologic diagnosis 
of anaplastic oligo-astrocytoma (AOA) but these two tumors 
have similar molecular profiles and are frequently categorized 
together in clinical treatment settings14,20,31). 
Although recent clinical trial results found benefits from ad-
juvant procarbazine, lomustine, and vincristine (PCV) chemo-
therapy, standard therapy for newly diagnosed AO/AOA is still 
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toxicities. All the toxicities relevant to TMZ chemotherapy were 
recorded and evaluated in reference to Common Terminology 
Criteria for Adverse Effect (CTCAE, version 3.0). For patients 
who experienced equal or more than grade 2 toxicities at the 
1st cycle, the dose was not elevated to the next level (i.e., 200 
mg/m2/day). We did not reduce or modify the TMZ dose ex-
cept the above grading and delayed the next cycle until patient 
completely recovered from the toxicities. 
Response and evaluation
The tumor response was evaluated by MRI taken at 3 or 6 
months after completion of 3 or 6 cycles of chemotherapy and 
at the time of suspicion of progression as compared to the base-
line MRI, which was taken at the time of recurrence. Macdon-
ald et al.15) for malignant glioma was adopted as the product of 
the maximal cross-sectional enhancing diameters are used to 
access tumor response. The PFS was defined as the time when 
the patients showed clinical deterioration with the evidence of 
radiological recurrence.
Statistical methods
The primary end point was the PFS, obtained by the Kaplan-
Meier method (SPSS software version 12.0, SPSS Inc., Chicago, 
IL, USA). We also calculated the radiological response rate and 
OS as the secondary end point. For the analysis of factors af-
fecting the PFS and OS, the Cox proportional hazard model 
was used to estimate the hazard ratio and corresponding 95% 
confidence interval (CI) on univariable analysis. Multivariable 
analysis included all the variables considered in the univariable 
analysis, and forward variable selection with selection criteria of 
0.05 was performed to determine the final model. Various factors 
related to radiological response were also verified by using Stu-
dent’s t-test and chi-square or Fisher’s exact test as appropriate.
RESULTS
Patient characteristics
Seventy-two patients from 19 medical centers, who had his-
tologically proven AO/AOA and underwent salvage TMZ che-
motherapy for their recurrent tumors between June 2006 and 
April 2010, were collected for retrospective analysis. The clini-
cal characteristics of the patients are summarized in Table 1. 
Their mean age was 47.8 years (range, 11-76). The number of 
male patients was 40 and the female was 32. Most patients (86%) 
were ambulatory and capable of self-care and had ECOG perfor-
mance score of 2 or less (29% with ECOG 0, 44% with ECOG 1 
and 13% with ECOG 2). Only 10 patients (14%) had ECOG 
scores of 3. In fifty seven patients, AO/AOA was an initial diag-
nosis of their tumor (de novo). At the time of diagnosis of WHO 
grade 3, 15 patients (21%) had a previous history WHO grade 2 
gliomas. Median time to recurrence from the initial diagnosis of 
AO/AOA was 9.0 months (range, 1-123). Forty patients (56%) 
had received surgical resection followed by radiation therapy, 
lighted for salvage treatment as it possesses good bioavailability 
although orally administered, and low cumulative toxicity such 
as myelosuppresion19). For recurrent malignant gliomas, TMZ 
chemotherapy showed improved progression-free survival (PFS) 
in patients with recurrent glioblastoma compared to PCV and 
revealed significant objective response rate of 35% in recurrent 
anaplastic astrocytoma and AOA at an acceptable, low rate of 
adverse events33,34).
However, a prospective clinical trial for evaluating the efficacy 
of TMZ salvage chemotherapy for this relatively rare AO/AOA 
has not been opened yet and several retrospective reports from 
single institutional experiences are not conclusive. Thus, our Ko-
rean Society for Neuro-Oncology (KSNO) group cooperated 
with Korean Health Insurance Review and Assessment (HIRA) 
to perform a multi-center, retrospective study to evaluate the ef-
ficacy and safety of TMZ salvage chemotherapy for recurrent 
AO/AOA. 
MATERIALS AND METHODS
Eligibility criteria 
Patients with histologically proven WHO grade 3 AO/AOA, 
who underwent TMZ chemotherapy for their recurrent tumors 
treated at the medical centers having Institutional Review Board 
qualified for multi-disciplinary study, had been asked for selec-
tive permission of HIRA for medical insurance coverage. The 
patients registered at HIRA database as who underwent TMZ 
salvage chemotherapy were considered to be enrolled in our 
study. Pathological diagnosis is confirmed by submission of the 
signed pathology report from each institution. After careful 
screening of case report form with pathology report of 95 pa-
tients from 19 medical centers, 23 patients who were lost with-
out follow-up images after TMZ chemotherapy, or no evidence 
of recurrence between the initial treatment and TMZ chemo-
therapy, or whose recurrence was from WHO grade 2 tumors 
were eliminated from the study. All patients were screened to re-
ceive TMZ chemotherapy about the following criteria : 1) surgi-
cally proven histopathology for initial WHO grade 3 AO/AOA; 
2) Eastern Cooperative Oncology Group (ECOG) performance 
status 3 or lower; 3) bone marrow function compatible to un-
dergo chemotherapy on complete blood count (CBC) profile 
(hemoglobin over 10 g/dL, leukocyte over 4000/µL, platelet 
over 100000/µL); 4) normal hepatic and renal function. 
Temozolomide chemotherapy protocol
TMZ was administered at 150 mg/m2/day for 5 days every 28 
days for the first cycle, with doses increased to 200 mg/m2/day 
for 5 days every 28 days for subsequent cycles if no grade 3/4 
toxicity was observed. Corticosteroids were not limited and ad-
ministered at a dose determined by attending physician. Patients 
were allowed to continue on this regimen until unacceptable tox-
icity or clinical/radiological disease progression. CBC and liver 
function test was done in the end of every cycle to monitor the 
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then chemotherapy with either PCV (70%) or other chemo-
therapy (TMZ in 5 patients, avastin-irinotecan in 4 patients, 
ACNU-CDDP in 2 patents, and BCNU-CDDP in one patient). 
Three patients, for whom conventional radiation therapy was 
performed at the time of low-grade diagnosis, underwent deb-
ulking surgery and received PCV chemotherapy only without 
radiation therapy. These forty-three patients were defined to 
chemo-experienced group.
Other 26 patients received surgical resection and conventional 
radiation therapy without adjuvant chemotherapy. Another three 
patients receiving debulking surgery underwent stereotactic ra-
diosurgery for their residual tumors. These 29 patients (40%) 
were chemo-naive before the enrollment to TMZ chemotherapy. 
Response to temozolomide
A median of TMZ chemotherapy cycles administered was 5.3 
(range, 1-41) and all the patients were evaluated to TMZ re-
sponse as we excluded the patients without follow-up MR image 
(Table 2). There were 8 patients (11%) who achieved complete re-
sponse and 9 patients (13%) who achieved partial response. 
Thus, objective response rate of TMZ salvage chemotherapy was 
24%. Another 23 patients (32%) remained in the range of stable 
disease and the tumors progressed in 32 patients (44%). Thus, tu-
mor stabilization rate was 56% in the patients. The response rates 
according to the histologic subtype were summarized in Table 2. 
The different histology of AO vs. AOA failed to show statistically 
significant difference in response rate although the response rate 
of 28% in AO patients was apparently higher than that of 14% in 
AOA patients. Gender, origin of tumor (de novo vs. secondary), 
previous chemotherapy experience, and other demographic vari-
ables categorized (i.e., age of <40 vs. ≥40, ECOG of 0-1 vs. 2-3, 
and time to recurrence after the initial treatment for AO/AOA of 
<1 year vs. ≥1 year) were evaluated for effect on the response rate. 
Among tested variables, the origin of tumor (de novo vs. second-
ary) was statistically significant as the secondary tumors showed 
a 53% response rate compared to the de novo tumors at 16% 
(p<0.01).
Toxicities
All toxicities recorded were graded according to the CTCAE 
version 3.0 and listed in Table 3. Hematologic side effects were 
observed in 16 patents (22%) but severe side effects (grade 3 or 
4) that caused delay of the next cycle occurred only in 6 patients 
(8%). Nausea and vomiting were recorded in 5 patients (7%) 
and one grade 4 nausea patient dropped out after one cycle by 
his wishes. Hepatotoxicity was only AST/ALT elevation (CT-
CAE grade 1 or 2) without other hepatobiliary symptoms in five 
patients but a grade 3 elevation up to 200/713 IU/L in one pa-
tient. All these abnormalities of hepatic enzymes returned to 
normal after either delay or termination of the TMZ therapy.
Progression-free survival and overall survival
Over the median image follow-up of 6.0 months (1 to 36 
Table 1. Clinical characteristics of patients
Characteristics n
Histology (%)
    AO    51 (71)
    AOA    21 (29)
Mean age (range) 47.8 (11-76)
Gender (%)
    Male    40 (56)
    Female    32 (44) 
ECOG scale (%)
    0    21 (29)
    1    32 (44)
    2      9 (13)
    3    10 (14)
Origin (%)
    De novo    57 (79)
    Secondary    15 (21)
Median time to recurrence (range) 9.0 months (1-123)
Previous treatment (%)
    Surgery+SRS      3 (4)
    Surgery+chemotherapy      3 (4)
    Surgery+radiation    26 (36)
    Surgery+radiation+chemotherapy    40 (56)
Median cycles of TMZ administered   5.3 (1-41)
AO : anaplastic oligodendroglioma, AOA : anaplastic oligo-astrocytoma, SRS : 
stereotactic radiosurgery, TMZ : temozolomide, ECOG : Eastern Cooperative On-
cology Group
Table 2. Response rate in patients with recurrent AO or AOA after sal-
vage TMZ chemotherapy
Response AO (n=51) AOA (n=21) Total (n=72)
Complete response   7 (14%)   1 (4.8%)   8 (11%)
Partial response   7 (14%)   2 (9.5%)   9 (13%)
Stable disease 17 (33%)   6 (29%) 23 (32%)
Progressive disease 20 (39%) 12 (57%) 32 (44%)
AO : anaplastic oligodendroglioma, AOA : anaplastic oligo-astrocytoma
Table 3. Toxicities in patients with recurrent AO or AOA after salvage 
TMZ chemotherapy
Side effects AO (n=51) AOA (n=21) Total (n=73)
Hematologic
    Grade 1 or 2 7 3 10 (14%)
    Grade 3 or 4 6 - 6 (8%)
Nausea/vomiting
    Grade 1 or 2 2 1 3 (4%)
    Grade 3 or 4* 2 2 (3%)
Hepatotoxicity
    Grade 1 or 2 4 1 5 (7%)
    Grade 3 or 4 - 1 1 (1%)
*One grade 4 nausea lead to discontinuation. AO : anaplastic oligodendroglioma, 
AOA : anaplastic oligo-astrocytoma, TMZ : temozolomide
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variate analysis (p=0.004 and 0.006, respectively) (Fig. 2B). 
‘Time-to-recurrence after the initial treatment for AO/AOA’  less 
than a year showed a tendency of negative influence on patients 
survival in univariate analysis (p=0.058) but failed to show sta-
tistical significance in multivariate analysis (p=0.079).
DISCUSSION
Treatment options for recurrent AO/AOA
Early studies of PCV chemotherapy for newly diagnosed or re-
current AO/AOA showed favorable response rate4,6,16,18). Based 
on those results, two phase 3 clinical trials (RTOG 9402 and 
EORTC 26951) of PCV adjuvant chemotherapy to surgery with 
radiation were launched5,27). Up-to-date reports of long-term fol-
low up from both studies prove long-term OS benefit and in-
creased long-term survival7,26). Thus, it can be expected for PCV 
chemotherapy to be adopted as one arm of standard therapy for 
AO/AOA. Hence, we need an effective salvage therapy for recur-
rent AO/AOA other than PCV chemotherapy21,24,29). However, to 
date, non-alkylating chemotherapy tried for chemo-experienced 
AO/AOA is not satisfactory. Chamberlain and Johnston9), ana-
lyzed data of bevacizumab for recurrent alkylator-refractory 
1p19q co-deleted AO patients. Similar to other bevacizumab-
based trials, initial response rate was fairly high (68%) but a me-
months), 49 patients showed progression. PFS of all patients was 
a median 8.0 months (95% CI, 6.0-10.0). Actuarial 6 months 
PFS rate was 52% and 1-year PFS 27%. Various clinical factors 
were evaluated to see if they can affect PFS (Table 4). By histol-
ogy, AO patients showed a median PFS of 8.0 months while 
AOA patients had a median PFS of 10.0 months but this appar-
ent difference did not reach the statistical significance (Fig. 1A). 
Among tested clinical factors, only the time to recurrence had 
significant influence on PFS as the patients recurred within a 
year showed a median PFS of 5.0 months, which was signifi-
cantly shorter than that of 11. 0 months in patients recurred at 
one year or after (p=0.04) (Fig. 1B) in univarable analysis but be-
came insignificant in multivariable analysis (p=0.07).
Patients were followed for a median of 11.5 months (range, 
2-66). As only 20 out of 72 patients died during the observation 
period, a median overall survival was not reached. The estimat-
ed 1-year survival rate was 81% and 2-year 63%. Clinical factors 
were also tested to see if they significantly affect the OS (Table 
5). AOA patients had a median OS of 18.0 months and 1-year OS 
rate of 76% while AO patients did not reach median OS and 
1-year OS rate was 83% but this apparent difference did not show 
statistical significance (Fig. 2A). Among various clinical factors, 
ECOG status of completely ambulatory or better (0 and 1) signif-
icantly prolonged patients survival in both univariate and multi-
Fig. 1. Kaplan-Meier progression-free survival in patients with recurrent AO or AOA after salvage TMZ chemotherapy (A) according to histopathology 
(AO vs. SOA, p>0.05) and (B) time to recurrence after the initial treatment for AO/AOA (<1 year vs. ≥1 year, p=0.04). AO : anaplastic oligodendroglio-
ma, AOA : anaplastic oligo-astrocytoma, TMZ : temozolomide.
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Table 4. Cox-proportional hazard model analysis of factors affecting patient’s progression-free survival after TMZ salvage chemotherapy
Factors
Univariable analysis Multivariable analysis
p value Hazard ratio 95% CI p value Hazard ratio 95% CI
Histopathology (AO vs. AOA) 0.52 1.23 0.65-2.33 0.35 1.38 0.70-2.71
Age (<40 vs. ≥40) 0.16 1.56 0.84-2.91 0.56 1.23 0.61-2.49
Gender (male vs. female) 0.27 1.37 0.78-2.41 0.17 1.49 0.84-2.66
ECOG (0-1 vs. 2-3) 0.97 1.01 0.52-1.99 0.88 1.06 0.52-2.13
Origin (de novo vs. secondary) 0.44 0.77 0.40-1.48 0.37 0.72 0.35-1.48
Time to recur (<1 year vs. ≥1 year) 0.04 0.53 0.29-0.99 0.07 0.52 0.26-1.05
Previous chemotherapy (naïve vs. experienced) 0.93 1.03 0.57-1.84 0.62 1.18 0.61-2.24
CI : confidence interval, ECOG : Eastern Cooperative Oncology Group, TMZ : temozolomide, AO : anaplastic oligodendroglioma, AOA : anaplastic oligo-astrocytoma
  AO
  AOA
Time to recur.
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ported 6.4% of grade 3 or 4 thrombocytopenia and dose-reduc-
tion was required only in 1.2% of total cycles. Two studies treat-
ed chemo-naïve recurrent oligodendrial tumors with TMZ with 
standard 5 days schedule3,30). van den Bent et al.28,30) observed 
grade 3/4 hematotoxicity in 10 out of 38 patients (26%) and 
dose reduced and delayed in 11% and 15% of patients with oli-
godendroglioma or oligoastrocytoma, respectively. Brandes et 
al.3) reported the occurrence of grade 3/4 hematotoxicity in 13% 
of patients with AO/AOA and needed dose reduction and de-
lays in 15% and 22% of patients, respectively. Although patients 
number was small (n=29), Yang et al.32) observed no significant 
toxicity with TMZ in Korean patients with malignant gliomas. 
However, these occurrences of SAE from TMZ should be pre-
sented with MGMT methylation status and need to be re-eval-
uated in future prospective study13). 
Response rate of TMZ in AO/AOA
The response rate of TMZ as 1st line salvage for (chemo-naïve) 
recurrent oligodendrial tumors was fairly high and similar to that 
of up-front or adjuvant TMZ therapy ranging 53-75%13,17,25). A 
prospective, phase 2 trial by van den Bent et al.30) revealed re-
sponse rate of 53% including a half of CR among responders in 
patients with recurrent oligodendroglioma or oligoastrocyto-
ma. Brandes et al.3) reported an overall response rate of 46% in-
dian PFS was only 6.8 months. The efficacy of irinotecan (CPT-
11) for recurrent chemo-experienced (TMZ or BCNU) AO 
patients was evaluated in phase 2 prospective trial, but only mod-
est effect was observed (28% of response rate, and median PFS 
of 4.5 months)8).
Safety of TMZ in AO/AOA
The virtues of TMZ for the treatment of malignant gliomas 
are good bioavailability in spite of per os administration, fairly 
high CNS penetration and most of all, good tolerance with a 
low rate of serious adverse events (SAE)14). Although TMZ itself 
is an alkylator carrying a high risk of cumulative hematotoxici-
ty, the reported rate of SAE is fairly acceptable even in a salvage 
treatment setting1,2,10,12,17,25,34). In our study, only one patient dis-
continued due to grade 4 nausea/vomiting and 6 patients (8%) 
delayed the next cycle for leucopenia/thrombocytopenia. Re-
ported SAE rate of TMZ ranged 6-31% according to dose sched-
ule or demographic factors1,2,12,13,17,25). Against the prejudication 
of more SAE in chemo-experienced patients than chemo-naïve 
patients, TMZ seemed to provoke equal or paradoxically less 
hematotoxicity in chemo-experienced settings compared with 
chemo-naïve one. Chinot et al.10) used the standard 5 days per 
28 days schedule for recurrent PCV-experienced AO/AOA, but 
dose modification scheme down to 50% were applied. They re-
Table 5. Cox-proportional hazard model analysis of factors affecting patient’s overall survival after TMZ salvage chemotherapy
Factors
Univariable analysis Multivariable analysis
p value Hazard ratio 95% CI p value Hazard ratio 95% CI
Histopathology (AO vs. AOA) 0.24 1.70 0.69-4.18 0.64 1.26 0.48-3.31
Age (<40 vs. ≥40) 0.75 0.85 0.31-2.34 0.84 0.89 0.27-2.88
Gender (male vs. female) 0.87 1.08 0.45-2.60 0.99 1.00 0.38-2.61
ECOG (0-1 vs. 2-3)   0.007 3.34 1.38-8.06   0.006 3.73 1.47-9.49
Origin (de novo vs. secondary) 0.41 1.86 0.43-8.09 0.34 2.14   0.45-10.24
Time to recur (<1 year vs. ≥1 year)   0.068 0.38 0.13-1.07   0.079 0.36 0.11-1.12
Previous chemotherapy (naive vs. experienced) 0.34 1.54 0.63-3.74 0.18 1.98 0.73-5.42
TMZ : temozolomide, CI : confidence interval, AO : anaplastic oligodendroglioma, AOA : anaplastic oligo-astrocytoma, ECOG : Eastern Cooperative Oncology Group
Fig. 2. Kaplan-Meier overall survival in patients with recurrent AO or AOA after salvage TMZ chemotherapy (A) according to histopathology (AO vs. 
AOA, p>0.05) and (B) ECOG performance status (0-1 vs. 2-3, p=0.007). AO : anaplastic oligodendroglioma, AOA : anaplastic oligo-astrocytoma, TMZ : 
temozolomide.
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Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of 
Korea (1120320).
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AOA (53% vs. 16%, p<0.01). But histologic type (AO vs. AOA) 
showed no difference of radiological response. We have a provi-
sion of gathering molecular profiles including 1p/19 co-dele-
tion and MGMT methylation status of these ‘clinically validat-
ed’ 72 recurrent AO/AOA patients as a second-term plan of the 
National R&D Program for Cancer Control, Ministry for 
Health, Welfare and Family Affairs, Republic of Korea.
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